WO2019222275A3 - Compositions and methods for tcr reprogramming using inducible fusion proteins - Google Patents

Compositions and methods for tcr reprogramming using inducible fusion proteins Download PDF

Info

Publication number
WO2019222275A3
WO2019222275A3 PCT/US2019/032298 US2019032298W WO2019222275A3 WO 2019222275 A3 WO2019222275 A3 WO 2019222275A3 US 2019032298 W US2019032298 W US 2019032298W WO 2019222275 A3 WO2019222275 A3 WO 2019222275A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
fusion proteins
compositions
tcr
inducible
Prior art date
Application number
PCT/US2019/032298
Other languages
French (fr)
Other versions
WO2019222275A2 (en
Inventor
Patrick Baeuerle
Daniel Getts
Vania ASHMINOVA
Michael Lofgren
Robert Hofmeister
Original Assignee
TCR2 Therapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TCR2 Therapeutics Inc. filed Critical TCR2 Therapeutics Inc.
Publication of WO2019222275A2 publication Critical patent/WO2019222275A2/en
Publication of WO2019222275A3 publication Critical patent/WO2019222275A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K39/464468—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

Provided herein are inducible T cell receptor (TCR) fusion proteins (TFPs) having specificity for one or more tumor cell associated antigens, T cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer, in particular for use in adoptive cell therapy.
PCT/US2019/032298 2018-05-14 2019-05-14 Compositions and methods for tcr reprogramming using inducible fusion proteins WO2019222275A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671342P 2018-05-14 2018-05-14
US62/671,342 2018-05-14

Publications (2)

Publication Number Publication Date
WO2019222275A2 WO2019222275A2 (en) 2019-11-21
WO2019222275A3 true WO2019222275A3 (en) 2020-08-20

Family

ID=68540969

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/032298 WO2019222275A2 (en) 2018-05-14 2019-05-14 Compositions and methods for tcr reprogramming using inducible fusion proteins

Country Status (1)

Country Link
WO (1) WO2019222275A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017024757A2 (en) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. compositions and methods for reprogramming tcr using fusion proteins
AU2017306432A1 (en) 2016-08-02 2019-03-21 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
PL3445787T3 (en) 2016-10-07 2021-05-31 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
BR112020024292A2 (en) 2018-06-06 2021-03-02 Massachusetts Institute Of Technology circular rna for translation into eukaryotic cells
WO2020219563A1 (en) * 2019-04-22 2020-10-29 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
JP2022533796A (en) 2019-05-22 2022-07-25 マサチューセッツ インスティテュート オブ テクノロジー Circular RNA compositions and methods
WO2020252436A1 (en) * 2019-06-14 2020-12-17 Flagship Pioneering Innovations Vi, Llc Circular rnas for cellular therapy
CA3160739A1 (en) 2019-12-04 2021-06-10 Brian Goodman Circular rna compositions and methods
BR112022018854A2 (en) * 2020-03-20 2023-03-07 Orna Therapeutics Inc CIRCULAR RNA COMPOSITIONS AND METHODS
WO2022056304A1 (en) * 2020-09-10 2022-03-17 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using nectin-4 specific fusion proteins
WO2022056321A1 (en) * 2020-09-10 2022-03-17 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using gpc3 specific fusion proteins
WO2022140388A1 (en) * 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
WO2022187591A1 (en) 2021-03-05 2022-09-09 Go Therapeutics, Inc. Anti-glyco-cd44 antibodies and their uses
EP4130028A1 (en) 2021-08-03 2023-02-08 Rhazes Therapeutics Ltd Engineered tcr complex and methods of using same
CA3226947A1 (en) 2021-08-03 2023-02-09 Muhammad YASSIN Engineered tcr complex and methods of using same
WO2023023150A2 (en) * 2021-08-18 2023-02-23 Hifibio (Hk) Limited Methods and compositions related to neutralizing antibodies against human coronavirus
WO2023172967A2 (en) * 2022-03-09 2023-09-14 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using gpc3 specific fusion proteins

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150087810A1 (en) * 2013-09-25 2015-03-26 Cytomx Therapeutics, Inc. Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
WO2017041749A1 (en) * 2015-09-11 2017-03-16 科济生物医药（上海）有限公司 Activatable chimeric receptor
WO2017162587A1 (en) * 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
WO2018067993A1 (en) * 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150087810A1 (en) * 2013-09-25 2015-03-26 Cytomx Therapeutics, Inc. Matrix Metalloproteinase Substrates And Other Cleavable Moieties And Methods Of Use Thereof
WO2017041749A1 (en) * 2015-09-11 2017-03-16 科济生物医药（上海）有限公司 Activatable chimeric receptor
WO2017162587A1 (en) * 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
WO2018067993A1 (en) * 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins

Also Published As

Publication number Publication date
WO2019222275A2 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
WO2018098365A3 (en) Compositions and methods for tcr reprogramming using fusion proteins
MX2021001009A (en) Compositions and methods for tcr reprogramming using target specific fusion proteins.
MX2021002225A (en) Compositions and methods for tcr reprogramming using fusion proteins.
MX2020009371A (en) Compositions and methods for tcr reprogramming using fusion proteins.
EA202090931A2 (en) COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING WITH HYBRID PROTEINS
GB2564823A (en) Compositions and methods for T-cell receptors reprogramming using fusion proteins
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
MX2019009468A (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer.
MX2020012927A (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy.
MX2020008333A (en) Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells.
MX2020008336A (en) Antibody variable domains targeting the nkg2d receptor.
MY189028A (en) Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
BR112017014551A2 (en) antibody, nucleic acid construct, expression vector, host cell, composition, methods for treating a disease, producing a bispecific antibody, and detecting the possible occurrence of crosslinking between cd3 and cd20-expressing cells in a derived sample of a patient, use of a bispecific antibody, and kit?
ES2851123T1 (en) Chimeric glypican-3-specific antigen receptors for adoptive immunotherapy
EP4273258A3 (en) Proteins binding her2, nkg2d and cd16
WO2020092848A3 (en) Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
WO2019232409A9 (en) Methods for genome editing and activation of cells
WO2020076977A3 (en) Dll3 single domain antibodies and therapeutic compositions thereof
MX2021001508A (en) Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of use.
MX2021001524A (en) Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use.
GB2596001A8 (en) Bispecific fusion protein using orthopoxvirus major histocompatibility complex (MHC) class 1-like protein (OMCP) and tumor-specific binding partner
ZA202205927B (en) Anti-yellow fever virus antibodies, and methods of their generation and use
WO2022081718A8 (en) Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19803199

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19803199

Country of ref document: EP

Kind code of ref document: A2